Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-02: Olomorasib plus immunotherapy in KRAS G12C-mutant NSCLC
ChiCTR2500111173Phase 3Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olomorasib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Part A: investigator-assessed disease-free survival and Part B: BICR-assessed progression-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500111173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111173.